Aprea's WEE1 Inhibitor Shows Second Partial Response in Endometrial Cancer Trial
Event summary
- Aprea Therapeutics reported a second unconfirmed partial response in the ACESOT-1051 trial for its WEE1 inhibitor APR-1051, observed in a patient with advanced endometrial cancer at the 220 mg dose level.
- The patient achieved a 50% tumor reduction and an 87% drop in CA-125 biomarker levels, with only Grade 1 adverse events.
- Both responding patients harbored PPP2R1A mutations, supporting the mechanistic thesis of targeting WEE1 for this patient population.
- The Phase 1 trial has treated 22 patients across doses ranging from 10 mg to 220 mg, with five patients showing stable disease.
The big picture
Aprea's latest data reinforces the potential of WEE1 inhibition in genomically defined cancers, particularly those with PPP2R1A mutations. The emerging clinical proof of concept without class-limiting toxicity supports Aprea's development strategy, positioning it in the competitive landscape of targeted oncology therapies. The focus on genomically guided patient selection aligns with broader industry trends toward precision medicine in cancer treatment.
What we're watching
- Clinical Validation
- Whether the second partial response will confirm the efficacy of APR-1051 in PPP2R1A-mutated tumors and support further genomic-guided patient selection.
- Dose Optimization
- The pace at which Aprea can determine the optimal dose for APR-1051 while maintaining its favorable safety profile.
- Competitive Differentiation
- How Aprea's strategy of differentiated WEE1 inhibition with an improved therapeutic index will position it against existing WEE1 inhibitors facing low therapeutic index challenges.
Related topics